September 23, 2021

Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative

September 23, 2021  – In 2020, Biogen launched its signature Healthy Climate, Healthy Lives™ initiative, a groundbreaking $250 million, 20-year commitment to address the deeply interrelated issues of climate, health, and equity. Biogen is the first Fortune 500 company to commit to becoming fossil

September 8, 2020

New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS

Data highlights socio-demographic and clinical disparities to help raise awareness of health inequities and inform future treatment planning Real-world data from MS PATHS identifies clinically relevant benchmarks to predict employment status among people with multiple sclerosis (MS) Biogen is

September 2, 2020

Biogen to Participate in the Morgan Stanley Virtual Global Healthcare Conference

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that it will participate in a live Q&A at the Morgan Stanley Virtual Global Healthcare Conference. The webcast will be live on Monday, September 14, at 10:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section

August 27, 2020

Biogen to Webcast Prerecorded Encore Aducanumab Presentation from 61st Annual Meeting of the Japanese Society of Neurology on August 31, 2020

Cambridge, Mass. – August 27, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a prerecorded webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming 61 st Annual Meeting of the Japanese Society of Neurology.

August 7, 2020

FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review

Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021 If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and TOKYO, Aug.

August 6, 2020

Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases

Biogen to receive license to co-develop and co-commercialize Denali’s small molecule LRRK2 inhibitor program, expanding pipeline of potential therapies in Parkinson’s disease and other movement disorders Biogen to receive exclusive option rights to two programs for neurodegenerative diseases

July 24, 2020

Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease

CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced there will be multiple data presentations from its Alzheimer’s disease (AD) clinical development portfolio, a virtual satellite symposium and AD PACE poster presentations at the Alzheimer’s Association

July 21, 2020

Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer

CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the appointment of Michael (Mike) McDonnell as Executive Vice President and Chief Financial Officer, effective August 15, 2020. McDonnell joins Biogen from IQVIA™ (NYSE: IQV), where he is Executive Vice

July 21, 2020

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)

In the long-term follow-up study of Zolgensma ® and real-world experience, it has been reported that some patients previously treated with gene therapy have been treated with SPINRAZA 1,2,3 The RESPOND study aims to evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical

July 13, 2020

Initiation of New Phase III Clinical Study (AHEAD 3-45) of BAN2401 Preclinical (Asymptomatic) Alzheimer’s Disease

Cambridge, Mass.— Biogen Inc.  (Nasdaq:BIIB) today announced ... edit content here ---- Edit content here -----To access the live webcast, please go to the investors section of Biogen’s website at . Following the live webcast, an archived version of the call will be

July 8, 2020

The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS

Tofersen is an investigational molecule for superoxide dismutase 1 ( SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative disease Final Phase 1/2 study results demonstrated proof-of-concept and proof-of-biology of tofersen, which is